{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:30:22Z","timestamp":1789353022627,"version":"build-2803163510"},"reference-count":34,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,5,10]]},"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To analyse the association between aminosalicylate-treated inflammatory bowel disease (IBD) and Parkinson\u2019s disease (PD) at population level.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>The study was performed based on electronic drug prescription and dispensation records of the Andalusian Public Health System.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>All individuals aged \u226550\u2009years with at least one drug dispensation during December 2014 were identified from the records.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Groups were formed: \u2018possible PD\u2019 group, including all who received an anti-Parkinson agent; \u2018possible IBD\u2019 group, those treated with mesalazine and\/or derivatives (5-aminosalicylic acid (5-ASA)); and \u2018possible PD and IBD\u2019, including those receiving both anti-Parkinson agent and 5-ASA. Prevalence of possible PD was determined among those with possible IBD and among those without this condition. The age-adjusted and sex-adjusted OR was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We recorded 2 020 868 individuals (68\u00b111\u2009years, 56% female), 19\u2009966 were included in possible PD group (75\u00b19\u2009years, 53% female) and 7485 in possible IBD group (64\u00b110\u2009years, 47% female); only 56 were included in both groups (76\u00b18\u2009years, 32% female). The prevalence of possible PD was 0.7% among those with possible IBD and 1% among those without this condition (adjusted OR=0.94; 95% CI 0.72 to 1.23; p=0.657). OR was 0.28 in individuals aged \u226465 years (95% CI 0.10 to 0.74; p=0.01) and 1.17 in older individuals (95% CI 0.89 to 1.54; p=0.257).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Within the limitations of this study, the results suggest a protective role for IBD and\/or 5-ASA against PD development, especially among under 65-year olds. Further studies are warranted to explore this association given its scientific and therapeutic implications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-025574","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T05:25:18Z","timestamp":1561008318000},"page":"e025574","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Association of Parkinson\u2019s disease and treatment with aminosalicylates in inflammatory bowel disease: a cross-sectional study in a Spain drug dispensation records"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9614-2278","authenticated-orcid":false,"given":"Javier","family":"Pinel R\u00edos","sequence":"first","affiliation":[{"name":"Neuroscience Unit, Hospital Vithas Xanit Internacional, Benalmadena, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Javier","family":"Madrid Navarro","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Virgen de las Nieves, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"P\u00e9rez Navarro","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Virgen de las Nieves, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Cabello Tapia","sequence":"additional","affiliation":[{"name":"Department of Digestive Diseases, Hospital Universitario Virgen de las Nieves, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Pi\u00f1a Vera","sequence":"additional","affiliation":[{"name":"Andalusian Health Service Pharmacy and Benefit Support Department, Andalusian Health Service, Government of Andalusia, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Campos Arillo","sequence":"additional","affiliation":[{"name":"Neuroscience Unit, Hospital Vithas Xanit Internacional, Benalmadena, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Rosario","family":"G\u00f3mez Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Digestive Diseases, Hospital Universitario Virgen de las Nieves, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"M\u00ednguez Castellanos","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Virgen de las Nieves, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Escamilla Sevilla","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hospital Universitario Virgen de las Nieves, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,6,19]]},"reference":[{"key":"2025121220232218000_9.6.e025574.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-002-0808-2"},{"key":"2025121220232218000_9.6.e025574.2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008762","article-title":"Progression of Parkinson\u2019s disease pathology is reproduced by intragastric administration of rotenone in mice","volume":"5","author":"Pan-Montojo","year":"2010","journal-title":"PLoS One"},{"key":"2025121220232218000_9.6.e025574.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1343-6"},{"key":"2025121220232218000_9.6.e025574.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1214-6"},{"key":"2025121220232218000_9.6.e025574.5","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000264429.59379.d9"},{"key":"2025121220232218000_9.6.e025574.6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25736"},{"key":"2025121220232218000_9.6.e025574.7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028032"},{"key":"2025121220232218000_9.6.e025574.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-015-1064-1"},{"key":"2025121220232218000_9.6.e025574.9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181c06635"},{"key":"2025121220232218000_9.6.e025574.10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/MIB.0000000000000735","article-title":"Association Between Parkinson\u2019s Disease and Inflammatory Bowel Disease: a Nationwide Taiwanese Retrospective Cohort Study","volume":"22","author":"Lin","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2025121220232218000_9.6.e025574.11","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddt465"},{"key":"2025121220232218000_9.6.e025574.12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai7795"},{"key":"2025121220232218000_9.6.e025574.13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.dld.2018.09.017","article-title":"The risk of Parkinson\u2019s disease in inflammatory bowel disease: A systematic review and meta-analysis","volume":"51","author":"Zhu","year":"2019","journal-title":"Dig Liver Dis"},{"key":"2025121220232218000_9.6.e025574.14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/mds.25979","article-title":"Enteric glial cells: new players in Parkinson\u2019s disease?","volume":"30","author":"Clairembault","year":"2015","journal-title":"Mov Disord"},{"key":"2025121220232218000_9.6.e025574.15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/MIB.0000000000000667","article-title":"Enteric glial cells: a new frontier in neurogastroenterology and clinical target for inflammatory bowel diseases","volume":"22","author":"Ochoa-Cortes","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"2025121220232218000_9.6.e025574.16","doi-asserted-by":"publisher","DOI":"10.1177\/0394632015599707"},{"key":"2025121220232218000_9.6.e025574.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2012.09.007"},{"key":"2025121220232218000_9.6.e025574.18","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/mds.25882","article-title":"Gut feelings about smoking and coffee in Parkinson\u2019s disease","volume":"29","author":"Derkinderen","year":"2014","journal-title":"Mov Disord"},{"key":"2025121220232218000_9.6.e025574.19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.parkreldis.2018.02.008","article-title":"Inflammatory bowel disease and risk of Parkinson\u2019s disease in Medicare beneficiaries","volume":"50","author":"Camacho-Soto","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"2025121220232218000_9.6.e025574.20","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.224154"},{"key":"2025121220232218000_9.6.e025574.21","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003961"},{"key":"2025121220232218000_9.6.e025574.22","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24448"},{"key":"2025121220232218000_9.6.e025574.23","first-page":"1","article-title":"Inflammatory bowel disease increases the risk of Parkinson\u2019s disease: a Danish nationwide cohort study 1977\u20132014","volume":"0","author":"Villumsen","year":"2018","journal-title":"Gut"},{"key":"2025121220232218000_9.6.e025574.24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/ibd\/izy190","article-title":"Inflammatory bowel disease and parkinson\u2019s disease: a nationwide swedish cohort study","volume":"25","author":"Weimers","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2025121220232218000_9.6.e025574.25","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1001\/jamaneurol.2018.0605","article-title":"Anti-tumor necrosis factor therapy and incidence of parkinson disease among patients with inflammatory bowel disease","volume":"75","author":"Peter","year":"2018","journal-title":"JAMA Neurol"},{"key":"2025121220232218000_9.6.e025574.26","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.67"},{"key":"2025121220232218000_9.6.e025574.27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2036.1993.tb00110.x","article-title":"Review article: the mode of action of the aminosalicylates in inflammatory bowel disease","volume":"7","author":"Greenfield","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121220232218000_9.6.e025574.28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/08923973.2016.1274997","article-title":"5-Aminosalicylic acid inhibits inflammatory responses by suppressing JNK and p38 activity in murine macrophages","volume":"39","author":"Qu","year":"2017","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2025121220232218000_9.6.e025574.29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04732.x"},{"key":"2025121220232218000_9.6.e025574.30","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/mds.25779","article-title":"Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects","volume":"29","author":"Gray","year":"2014","journal-title":"Mov Disord"},{"key":"2025121220232218000_9.6.e025574.31","doi-asserted-by":"crossref","unstructured":"Zhang W , Gao JH , Yan ZF , et al . Minimally toxic dose of lipopolysaccharide and \u03b1-synuclein oligomer elicit synergistic dopaminergic neurodegeneration: role and mechanism of microglial NOX2 activation. Mol Neurobiol 2016.","DOI":"10.1007\/s12035-016-0308-2"},{"key":"2025121220232218000_9.6.e025574.32","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2015.1009448"},{"key":"2025121220232218000_9.6.e025574.33","doi-asserted-by":"publisher","DOI":"10.1177\/039463200902200405"},{"key":"2025121220232218000_9.6.e025574.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.11.018"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-025574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T04:23:30Z","timestamp":1765599810000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-025574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6,19]]},"published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1136\/bmjopen-2018-025574"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-025574","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}